Renal Cell Carcinoma: Weighing PFS Versus Overall Survival

In this segment, Dr. Elizabeth Plimack and Dr. Yasser Ged examine how clinicians interpret progression-free survival and overall survival when evaluating first-line treatment options in renal cell carcinoma. Dr. Ged discusses the complementary roles of these endpoints, noting that progression-free survival can provide earlier insight into disease control, while overall survival remains the most definitive measure of long-term benefit. The conversation highlights how the relative importance of each endpoint may vary depending on clinical context, including patient symptoms, disease burden, and urgency of response. Dr. Ged emphasizes that progression-free survival can be particularly informative in assessing the immediate impact of therapy, whereas overall survival helps guide broader treatment strategy and expectations. This segment underscores the importance of integrating multiple efficacy endpoints to support nuanced, patient-specific decision-making in renal cell carcinoma.